Painless injection start-up Sindolor raises $1m

D Medical led the round and owns over half of the company.

Medical device start-up Sindolor Ltd. has raised $1 million at a company value of $2.4 million. D Medical Industries Ltd. (TASE:DMDC) led the round, with an investment of $756,000 and now owns 57.5% of the company. Most of Sindolor's shareholders participated in the round.

Sindolor is developing what it calls a painless drug delivery system for regular subcutaneous injection using proprietary safety needles based on its proprietary EZject technology. The product has already been approved for marketing in the US.

Sindolor was founded on the ruins of a company that went into receivership. D Medical acquired 50.1% of the company for $1.5 million, a $1.86 million owners' loan, and $840,000 to cover debts. D Medical recently announced that Sindolor was about to sign a contract with a large pharmaceutical company for joint distribution of Sindolor's product. If a deal is closed, it could be worth tens of millions of dollars over several years.

Published by Globes [online], Israel business news - www.globes-online.com - on March 13, 2008

© Copyright of Globes Publisher Itonut (1983) Ltd. 2008

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Joseph Papa Perrigo up for sale

The pharmaceutical firm is seeking a merger at a premium on its $20 billion market cap.

Twitter Facebook Linkedin RSS Newsletters גלובס